Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063958 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
A Phase 1 study of Cancer, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 5
- Study locations
NCT02063958: Completed Phase 1 study of Cancer, sponsored by Esanex.
NCT02063958 is a Phase 1 study of Cancer that has completed, run by Esanex. The registered enrollment target is 19 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02063958, a Phase 1 study of Cancer, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 5
- Study locations
Study Summary
Study is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in combination with everolimus.
Primary Outcome
Number of patients with dose limiting toxicities defined as adverse events or laboratory abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 ≥ Grade 3 that are not clearly related to disease progression or delay by more than 4 weeks in receiving the next scheduled cycle due to persisting toxicities and attributable to the combination of SNX-5422 and everolimus despite optimal medical supportive management.
Conditions Studied
Interventions
- DRUG SNX-5422
Study Locations (5)
Arizona
- Mayo Clinic - Scottsdale
California
- Stanford Medicine - Stanford
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Maryland
- Center for Cancer Research, National Cancer Institute - Bethesda
New Jersey
- hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-03-20 |
| Phase | Phase 1 |
What the finished NCT02063958 record still lists
NCT02063958 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which SNX-5422 is the first listed.
NCT02063958 lists 5 locations in 5 states (Arizona, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02063958 about?
NCT02063958 is a clinical study titled "Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors". Study is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in combination with everolimus.
What is the current status of trial NCT02063958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-02. Estimated completion is 2018-03-20.
What conditions does trial NCT02063958 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT02063958?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT02063958?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02063958 being conducted?
This trial has 5 study locations across Arizona, California, District of Columbia, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02063958's enrollment target sits among peer trials
19 570th of 615 higher than 45 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia